Alexandra Manick
Principal @ Schooner Capital
Boston, United States
Alexandra Manick is a Series A investor at Schooner Capital in Boston focused on Medical and Robotics. Alexandra Manick is the Associate Principal at Schooner Capital. Alexandra Manick attended Stanford University Graduate School of Business.
- Total investments:
- 3
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Alexandra Manick invests in
Stages Alexandra Manick invests in
Countries Alexandra Manick invests in
Investment Focus
Industry
- Medical 1 (33%)
- Robotics 1 (33%)
- Analytics 1 (33%)
- 3D Printing 1 (33%)
- Construction 1 (33%)
Stage
- Series A 1 (33%)
- Series C 1 (33%)
- Venture - Series Unknown 1 (33%)
Country
- United States 2 (67%)
- Germany 1 (33%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
KEWAZO
|
KEWAZO is digitizing construction with robotics and data analytics. We integrate robotic platforms on-site to enable digital services. In scaffolding, our robotic material hoist LIFTBOT saves up to 44% of labor costs, addresses labor shortage, and improves safety. By having our robots on-site, we collect operational data and provide it to ourcustomers in the form of a data analytics platform, enabling more proactive management of both individual projects and companies overall. | $16M / Series A / Mar 19, 2026 | |
Remedy Plan Therapeutics
|
Remedy Plan Therapeutics is a pre-clinical-stage company developing small molecule therapeutics to halt tumor growth and disrupt the cancer stem cells that cause metastasis. Our approach is to develop effective, non-toxic treatments that target the dangerous embryonic properties of cancer stem cells, which form the basis for cancer growth, spread,and resistance to chemotherapy. Remedy Plan is positioned to deliver one first-in-class drug candidate for Phase I clinical development approximately 15 months after Series A fundingRemedy Plan's proprietary drug screening platform identifies drug candidates that differentiate cancer stem cells, disrupt proliferation, and inhibit formation of new tumors. From the initial screen of 40,000 drug components, a lead candidate is currently undergoing optimization and mechanism of action studies in preparation for Phase I clinical trials. With the second screen of over 100,000 drug components completed, Remedy Plan aims to have at least two drugs in clinical development by 2020. | $18M / Venture - Series Unknown / May 13, 2025 | |
Mantle
|
Mantle is an engineering and manufacturing company that has developed metal 3D printing technology to produce high-resolution parts that meet the critical needs of applications from automotive and aerospace to consumer product design and prototyping. | $20M / Series C / Jul 10, 2024 |
Co-Investors
About Schooner Capital
Schooner Capital is a private investment office. The firm has no outside limited partners and approaches all investments with a long-term perspective.
Schooner Capital Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alexandra Manick
Principal
|
|||
Jake Fiechter
Analyst
|
|||
|
Jon Corbett
Vice President of Finance
|
|||
|
Lou Stathis
Accountant
|
|||
|
Orhan Gazelle
Principal; Managing Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Alexandra Manick invest in?
Alexandra Manick invests primarily in Medical, Robotics and Analytics startups, most often at Series A and Series C stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Alexandra Manick last invest?
The most recent investment recorded for Alexandra Manick closed in Mar 2026. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
